Physician

Gopal R. Kunta, M.D.

According to 2025 Medicare claims, Gopal Kunta, M.D. (NPI: 1043209950) practices medical oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is CLERMONT ONCOLOGY CENTER LLC (NPI: 1851701239; TIN: 465180824) and primary practice location at 34711-1924. Kunta is affiliated with the Community Care Partnership of Maine, LLC (ACO ID: A2831) and Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Kunta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 642 traditional Medicare patients, billed 439,427 HCPCS/CPT codes, and received $3,484,239 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,921 prescription claims across 445 beneficiaries totaling $10,116,631 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 26 claims. Open Payments data shows 177 records totaling $368,135. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,194,749 to $3,484,239. Similarly, Part D prescription costs have risen steadily, from $612,372 to $10,116,631. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,531 and ending at $8,680.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	388	84,457	$1,194,749
2016	483	128,153	$1,298,280
2017	582	155,259	$1,910,036
2018	656	433,570	$2,212,803
2019	673	287,483	$2,841,652
2020	655	390,932	$3,602,166
2021	648	370,017	$3,460,238
2022	634	364,551	$3,330,295
2023	627	478,224	$3,051,976
2024	642	439,427	$3,484,239

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	143	659	$612,372
2016	202	909	$1,427,812
2017	240	1,292	$2,562,550
2018	322	1,789	$4,192,631
2019	342	2,053	$6,012,256
2020	411	2,710	$7,845,791
2021	448	3,041	$8,625,990
2022	450	2,661	$8,948,749
2023	428	2,562	$9,273,999
2024	445	2,921	$10,116,631

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	31	$940
2016	N/R	88	$3,570
2017	N/R	50	$7,099
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	26	$59,983
2021	N/R	28	$1,704
2022	N/R	22	$46,234
2023	N/R	26	$55,344
2024	N/R	26	$56,879

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	470	1,447	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	201	283	$68
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	188	1,325	$47
36415	Insertion of needle into vein for collection of blood sample	558	2,455	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	548	2,442	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	86	2,268	$1,777,164
Xtandi	Enzalutamide	87	2,610	$1,166,788
Revlimid	Lenalidomide	46	1,260	$809,531
Darzalex	Daratumumab	72	2,020	$793,988
Lupron Depot	Leuprolide Acetate	91	8,448	$542,913

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1556	Injection, immune globulin (bivigam), 500 mg	N	N/R	13	$52,594
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	13	$4,285

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	106	$4,811	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	71	$363,324	Regeneron Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gopal R. Kunta, M.D.?

Tedicare shows public-source Medicare data for Gopal R. Kunta, M.D. (NPI 1043209950), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gopal R. Kunta, M.D. have ACO affiliation data?

Gopal R. Kunta, M.D. is shown with ACO affiliation data for Community Care Partnership of Maine, LLC (MSSP, ACO ID A2831) and Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Gopal R. Kunta, M.D.?

Gopal R. Kunta, M.D. is linked to CLERMONT ONCOLOGY CENTER LLC (billing NPI 1851701239) in the available physician profile data.

Does Gopal R. Kunta, M.D. have Open Payments data?

Gopal R. Kunta, M.D. has 177 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.